Benign Breast Disease: Toward Molecular Prediction of Breast Cancer Risk
Abstract
Optimal early detection and prevention strategies for breast cancer are predicated on our ability to identify individuals at significantly increased risk for this disease. The purpose of this Center was to bring molecular risk prediction for breast cancer into the clinical arena. The three areas of scientific inquiry included:(i) Establishment of a tissue repository of benign breast disease; (ii) Assessment of potential biomarkers of risk in this tissue set and (iii) Discovery of new, potentially relevant biomarkers of risk. We developed a cohort of 9,376 women, 758 (8%) of whom have been diagnosed with breast cancer since the time of their benign biopsy. We established our tissue repository of benign breast tissue and have collected the subsequent breast cancer tissue. We assessed the significance of benign histology in predicting the risk of future breast cancer, examining in detail the role of proliferative disease, atypia, papillomas, radial scars and involution. We explored the link between centrosome amplification, COX-2 expression, ER, Ki67 and breast cancer outcomes. Lastly, we characterized the histopathology in a cohort of African-American women that we established with Wayne State University.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2009
- Accession Number
- ADA552165
Entities
People
- Lynn C. Hartmann
Organizations
- Mayo Clinic